Physician profile
Shashank Cingam
NPI 1639552870
$6,867.55
in general payments reported to CMS, 2019-2025
25 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $350 · 2022: $112 · 2023: $1,935 · 2024: $3,338 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,025 · Travel and Lodging: $1,702 · Food and Beverage: $1,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,025.00 |
| Travel and Lodging | $1,701.95 |
| Food and Beverage | $1,557.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $3,025.00 | 2024 | Tecvayli |
| Abbvie INC. | $1,958.54 | 2023-2025 | Epkinly, Venclexta |
| Incyte Corporation | $270.13 | 2020-2025 | Niktimvo, Jakafi |
| Celgene Corporation | $236.76 | 2024-2025 | Pomalyst, Breyanzi, Reblozyl |
| Karyopharm Therapeutics INC. | $233.58 | 2020-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $228.16 | 2019-2020 | |
| Pfizer INC. | $151.52 | 2025 | |
| Sanofi-Aventis U.S. LLC | $125.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2025 | Breyanzi |
| Novartis Pharmaceuticals Corporation | $112.30 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $49.19 | 2025 | Lynozyfic |
| Genentech USA, INC. | $42.65 | 2025 | Polivy, Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $34.94 | 2025 | Iclusig, Ninlaro |
| Beone Medicines USA, INC. | $34.91 | 2025 | Brukinsa |
| Daiichi Sankyo INC. | $29.69 | 2025 | Enhertu |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $27.24 | 2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $25.24 | 2025 | Calquence |
| Adaptive Biotechnologies Corporation | $24.49 | 2025 | Clonoseq |
| Glaxosmithkline, LLC. | $24.30 | 2025 | Ojjaara |
| Astellas Pharma US INC | $23.56 | 2025 | Xospata |
| Genzyme Corporation | $20.32 | 2025 | |
| Apellis Pharmaceuticals, INC. | $19.83 | 2025 | |
| Legend Biotech USA INC. | $18.66 | 2024 | |
| Janssen Biotech, INC. | $15.35 | 2025 | Talvey, Darzalex |
| Merck Sharp & Dohme LLC | $11.19 | 2025 | Keytruda, Keytruda Qlex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shashank Cingam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.